Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Hoffmann-La Roche
Modality
Small molecule
Development Phase
Phase 3
Status
Dormant
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
52High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04222972CT.gov A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT03037385CT.gov Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Nervous System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pralsetinib, Trans- (this asset) | Hoffmann-La Roche | P3 | BB · 64 |
| Carboplatin | Blueprint Medicines Corporation | P3 | BB |
| Pembrolizumab | Hoffmann-La Roche | P3 | BB |
| Microbubble | NaviFUS Corporation | P3 | B |
| Cis-Diamminedichloroplatinum Ii | Hoffmann-La Roche | P3 | B |
| Armodafinil | Wake Forest University Health Sciences | P2 | B |
| Tasadenoturev | DNAtrix, Inc. | P2 | B |
| Interleukin-12 | Second Affiliated Hospital, School of Medicine, Zhejiang University | P1/2 | CC |
| Sulfur Hexafluoride | NaviFUS Corporation | P1/2 | CC |
+5 more in the Nervous System Neoplasm cohort
Other indications for Pralsetinib, Trans-
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Neoplasm | — | P3 | BB · 67 |
| Germ Cell Tumor | — | P3 | BB · 66 |
| Respiratory System Disorder | — | P3 | BB · 66 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pralsetinib, Trans- in Nervous System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pralsetinib-trans-nervous-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →